![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
E. D’Amico, F. Patti, A. Zanghì, S. Lo Fermo, C.G. Chisari & M. Zappia. (2018) Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Review of Clinical Pharmacology 11:5, pages 531-536.
Read now
Read now
Kendra L Furber, Marina Van Agten, Charity Evans, Azita Haddadi, J Ronald Doucette & Adil J Nazarali. (2017) Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a. Degenerative Neurological and Neuromuscular Disease 7, pages 47-60.
Read now
Read now
Baris Deniz. (2015) Author’s Response to Letter to the Editor. Current Medical Research and Opinion 31:1, pages 53-55.
Read now
Read now
Kristin A Hanson, Neetu Agashivala, Sonja M Stringer, Zaneta Balantac & David W Brandes. (2013) A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod. Patient Preference and Adherence 7, pages 309-318.
Read now
Read now
Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Allison Petrilla, Swapna U. Karkare, Catherine Balderston McGuiness & Jonathan R. Korn. (2013) Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Current Medical Research and Opinion 29:12, pages 1647-1656.
Read now
Read now
Articles from other publishers (29)
Christopher Drudge, Imtiaz A Samjoo, Róisín Brennan, Lohit Badgujar, Vivek Khurana, Santosh Tiwari, Nicholas Adlard & Judit Banhazi. (2023) An overview of reviews with network meta-analyses comparing disease-modifying therapies for relapsing multiple sclerosis. Future Neurology 18:3.
Crossref
Crossref
Fatemeh Fakhr, Vahid Shaygannejad, Mehdi Khorrami, Leila Saberi, Omid Mirmosayyeb, Erfan Sadeghi & Majid Kheirollahi. (2023) ADAR Expression and Single Nucleotide Variants in Multiple Sclerosis Patients Affect the Response to Interferon Beta Therapy. Global Medical Genetics 10:03, pages 164-171.
Crossref
Crossref
Sangharsha Thapa, Sangam Shah, Aastha Subedi, Sara Bagherieh, Swati Chand, Omid Mirmosayyeb & Svetlana Primma Eckert. (2022) Efficacy and Safety of Ponesimod in Relapsing Multiple Sclerosis: A Systematic Review. Neurology and Clinical Neuroscience 10:6, pages 305-314.
Crossref
Crossref
Mohamed Toufic El Hussein & Ashley Wong. (2022) Using Mnemonic in Management of Multiple Sclerosis. Journal of Neuroscience Nursing 54:1, pages 48-51.
Crossref
Crossref
Xin Wu, Tao Xue, Zilan Wang, Zhouqing Chen, Xuwei Zhang, Wei Zhang & Zhong Wang. (2021) Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 12.
Crossref
Crossref
Jagadeswara R. Earla, George J. Hutton, Douglas J. Thornton, Hua Chen, Michael L. Johnson & Rajender R. Aparasu. (2021) Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:5, pages 440-450.
Crossref
Crossref
Recep Yevgi & Recep Demir. (2021) Oxidative stress activity of fingolimod in multiple sclerosis. Clinical Neurology and Neurosurgery 202, pages 106500.
Crossref
Crossref
D. Schriefer, R. Haase, B. Ettle & T. Ziemssen. (2020) Patient‐ versus physician‐reported relapses in multiple sclerosis: insights from a large observational study. European Journal of Neurology 27:12, pages 2531-2538.
Crossref
Crossref
Xin Tian, Chaoyang Chen, Lingyun Ma, Ran Wei, Min Li, Xiaoqing Wang, Ye Wu, Ying Zhou & Yimin Cui. (2020) Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. Journal of Neuroimmunology 347, pages 577317.
Crossref
Crossref
Bonnie I. Glanz, Jonathan Zurawski, Cindy T. Gonzalez, Rebecca Shamah, Adrianna Ratajska, Tanuja Chitnis, Howard L. Weiner & Brian C. Healy. (2020) Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders 40, pages 101944.
Crossref
Crossref
Ting Yang, Xin Tian, Chao‐Yang Chen, Ling‐Yun Ma, Shuang Zhou, Min Li, Ye Wu, Ying Zhou & Yi‐Min Cui. (2020) The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta‐analysis. British Journal of Clinical Pharmacology 86:4, pages 637-645.
Crossref
Crossref
Judith Haas, Douglas Jeffery, Diego Silva, Daniela Piani Meier, Rolf Meinert, Jeffrey Cohen & Hans-Peter Hartung. (2019) Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Multiple Sclerosis and Related Disorders 36, pages 101335.
Crossref
Crossref
Brian C. Healy, Bonnie I. Glanz, Jonathan D. Zurawski, Maria Mazzola, Tanuja Chitnis & Howard L. Weiner. (2018) Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. Journal of the Neurological Sciences 394, pages 127-131.
Crossref
Crossref
Ramin Ravangard, Mehdi Rezaee, Khosro Keshavarz, Afshin Borhanihaghighi & Sadegh Izadi. (2018) Cost - effectiveness and Cost - utility of CinnoVex versus ReciGen in Patients with Relapsing - Remitting Multiple Sclerosis in Iran. Shiraz E-Medical Journal In Press:In Press.
Crossref
Crossref
Andrew Chan, Gary Cutter, Robert J Fox, James Xiao, James B Lewin & Michael R Edwards. (2017) Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research 6:4, pages 313-323.
Crossref
Crossref
Gurpreet K. Reen, Eli Silber & Dawn W. Langdon. (2017) Interventions to support risk and benefit understanding of disease-modifying drugs in Multiple Sclerosis patients: A systematic review. Patient Education and Counseling 100:6, pages 1031-1048.
Crossref
Crossref
Josephine Mauskopf, Stephanie R. Earnshaw, Anita Brogan, Sorrel Wolowacz & Thor-Henrik BrodtkorbSorrel Wolowacz, Josephine Mauskopf & Stephanie Earnshaw. 2017. Budget-Impact Analysis of Health Care Interventions. Budget-Impact Analysis of Health Care Interventions
91
101
.
Diogo Mendes, Carlos Alves & Francisco Batel-Marques. (2016) Benefit–Risk of Therapies for Relapsing–Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis. CNS Drugs 30:10, pages 909-929.
Crossref
Crossref
Keith Tolley, Michael Hutchinson, Xiaojun You, Ping Wang, Bjoern Sperling, Ankush Taneja, Mohammed Kashif Siddiqui & Elizabeth Kinter. (2015) A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. PLOS ONE 10:6, pages e0127960.
Crossref
Crossref
Simon A. Broadley, Michael H. Barnett, Mike Boggild, Bruce J. Brew, Helmut Butzkueven, Robert Heard, Suzanne Hodgkinson, Allan G. Kermode, Jeannette Lechner-Scott, Richard A.L. Macdonell, Mark Marriott, Deborah F. Mason, John Parratt, Stephen W. Reddel, Cameron P. Shaw, Mark Slee, Judith Spies, Bruce V. Taylor, William M. Carroll, Trevor J. Kilpatrick, John King, Pamela A. McCombe, John D. Pollard & Ernest Willoughby. (2014) Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. Journal of Clinical Neuroscience 21:11, pages 1847-1856.
Crossref
Crossref
Daniel Ontaneda, Samuel Cohn & Robert J. Fox. (2014) Risk stratification and mitigation in multiple sclerosis. Multiple Sclerosis and Related Disorders 3:5, pages 639-649.
Crossref
Crossref
Alan M. Palmer. (2014) New and emerging immune-targeted drugs for the treatment of multiple sclerosis. British Journal of Clinical Pharmacology 78:1, pages 33-43.
Crossref
Crossref
Martin Duddy, Martin Lee, Owen Pearson, Esmaeil Nikfekr, Abhijit Chaudhuri, Fran Percival, Megan Roberts & Carolyn Whitlock. (2014) The UK patient experience of relapse in Multiple Sclerosis treated with first disease modifying therapies. Multiple Sclerosis and Related Disorders 3:4, pages 450-456.
Crossref
Crossref
Renaud A. Du Pasquier, Daniel D. Pinschewer & Doron Merkler. (2014) Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis. CNS Drugs 28:6, pages 535-558.
Crossref
Crossref
Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Allison A. Petrilla, Swapna U. Karkare, Catherine Balderston McGuiness & Jonathan R. Korn. (2014) Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. PLoS ONE 9:2, pages e88472.
Crossref
Crossref
David J. Graber & William F. Hickey. 2014. Neuroinflammation and Neurodegeneration. Neuroinflammation and Neurodegeneration
547
567
.
Paul W. O’Connor, Fred D. Lublin, Jerry S. Wolinsky, Christian Confavreux, Giancarlo Comi, Mark S. Freedman, Tomas P. Olsson, Aaron E. Miller, Catherine Dive-Pouletty, Gaëlle Bégo-Le-Bagousse & Ludwig Kappos. (2013) Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of Neurology 260:10, pages 2472-2480.
Crossref
Crossref
Mohammed Aljumah, Raed Alroughani, I. Alsharoqi, Saeed A. Bohlega, Maurice Dahdaleh, Dirk Deleu, Khaled Esmat, Ahmad Khalifa, Mohammad A. Sahraian, Miklós Szólics, Abdulrahman AlTahan, Bassem I. Yamout, Peter Rieckmann & Abdulkader Daif. (2013) Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries. Multiple Sclerosis International 2013, pages 1-6.
Crossref
Crossref
Alan M. Palmer. (2012) Pharmacotherapeuetic Options for the Treatment of Multiple Sclerosis. Clinical Medicine Insights: Therapeutics 4, pages CMT.S8661.
Crossref
Crossref